The impact of body weight on rivaroxaban pharmacokinetics.
Sarah J BarsamJignesh P PatelLara N RobertsVenu KavarthapuRaj K PatelBruce GreenRoopen AryaPublished in: Research and practice in thrombosis and haemostasis (2017)
Our results suggest that the most important covariate impacting on rivaroxaban pharmacokinetics is creatinine clearance and the weight alone has little effect. These findings are in line with previous studies for rivaroxaban. Larger datasets, from real-world patients who are followed longitudinally, should be conducted to provide front-line clinicians with further reassurance when prescribing rivaroxaban for the acute management of VTE.
Keyphrases
- venous thromboembolism
- body weight
- atrial fibrillation
- pulmonary embolism
- end stage renal disease
- ejection fraction
- newly diagnosed
- primary care
- chronic kidney disease
- liver failure
- body mass index
- palliative care
- peritoneal dialysis
- prognostic factors
- weight loss
- respiratory failure
- drug induced
- weight gain
- metabolic syndrome
- case control
- rna seq
- hepatitis b virus
- extracorporeal membrane oxygenation
- electronic health record
- single cell